It is the third company to be launched by the USA-based orphan drug accelerator, Cydan, and is advancing two compounds licensed from French drugmaker Ipsen, TBR-760 for the treatment of non-functioning pituitary adenoma and TBR-065 for additional rare endocrine diseases.

As part of the launch, Tiburio raised a $31 million series A financing.